ArticleGeneral thoracic and cardiovascular surgery2026
Prognostic comparison between superior and basal segments in pure-solid non-small cell lung cancer.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Critical appraisal of "Prognostic impact of pure-solid non-small cell lung cancer in the superior versus basal segment of the lower lobe following lobectomy".General thoracic and cardiovascular surgery · 2026Article
- Lymph Node Metastasis and Recurrence Patterns in Clinical Stage IA Lower-Lobe Non-Small Cell Lung Cancer: Toward an Optimal Surgical Strategy for Superior Segment (S6) Tumors.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStudies suggest that non-small cell lung cancer of the superior segment (S6) affects different lymphatic pathways and results in worse prognosis than basal segment tumors. We aimed to compare survival after lobectomy between non-small cell lung cancer in the S6 and basal segments, focusing specifically on pure-solid tumors, which have higher lymph node metastasis rates and worse prognosis.
methodsWe retrospectively reviewed patients with pure-solid, clinical N0 M0, ≤ 5-cm, lower-lobe non-small cell lung cancer who underwent lobectomy with hilar and mediastinal lymphadenectomy between April 2009 and December 2021. Overall survival, recurrence-free survival and clinicopathological characteristics were evaluated.
resultsWe categorized 157 patients into S6 (n = 58) and basal segment (n = 99) groups. The 5-year overall survival (66.4% vs. 68.6%, respectively; p = 0.519; hazard ratio, 1.19; 95% confidence interval, 0.70-2.03), and recurrence-free survival (54.8% vs. 65.5%, respectively; p = 0.452; hazard ratio, 1.22; 95% confidence interval, 0.72-2.06) rates were comparable between the S6 and basal segment groups. Multivariable Cox regression analyses indicated that tumor location was not associated with overall or recurrence-free survival. The S6 group showed a higher tendency for visceral pleural invasion compared with the basal segment group. Superior mediastinal lymph node metastasis was pathologically confirmed exclusively in the S6 group (two cases).
conclusionsNo significant difference in survival was observed between S6 and basal segment pure-solid non-small cell lung cancer after lobectomy with hilar and mediastinal lymph node dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.